All Updates

All Updates

icon
Filter
M&A
MilliporeSigma acquires Mirus Bio for USD 600 million to enhance viral vector manufacturing capabilities
Cell & Gene Therapy
May 23, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Yesterday
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Yesterday
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Yesterday
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Yesterday
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Yesterday
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Yesterday
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Yesterday
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Yesterday
Regulation/policy
Product updates
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Yesterday
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

May 23, 2024

MilliporeSigma acquires Mirus Bio for USD 600 million to enhance viral vector manufacturing capabilities

M&A

  • MilliporeSigma, the Life Science business branch of Merck KGaA (based in the US and Canada), has finalized a deal to buy Mirus Bio for USD 600 million.

  • Mirus Bio is known for its expertise in the development and commercialization of transfection re-agents, under the name TransIT-VirusGEN, which are instrumental in transferring genetic material into cells. This makes them essential in the creation of viral vectors, a crucial element in the design of cell and gene therapies.

  • This acquisition is intended to bolster Merck's capabilities in viral vector manufacturing for gene and cell therapies. With the added competency of Mirus Bio, Merck aims to provide comprehensive solutions for all phases of viral vector manufacturing, thereby supporting the progression of cell and gene therapies from preliminary stages to final commercial production.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.